



**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**2201 Shannon Place SE – 2ND FLR
WASHINGTON, DC 20020**

WebEx Virtual MEETING

**August 20, 2024
10 AM—11:30 PM**

AGENDA

CALL TO ORDER:**PRESIDING:****COMMITTEE MEMBERSHIP/ATTENDANCE:**

ADVISORY COMMITTEE MEMBERS:		
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director, Program Manager Pharmaceutical Control Division	
	Aisha Nixon, MPT, CPM, Associate Director	
	Sithembile Chithenga, MD, Board of Medicine Executive Director	
	Vito R. DelVento, DVM, MS, Board of Veterinary Medicine Executive Director, Program Manager Animal Services Program	
	Ericka L. Walker, MSW Interim Executive Director Board of Nursing	
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	
	Sheri Doyle, MPH, Consumer Member	
	Captain Shawn Rooney, Metropolitan Police Department	
	Sharon Hunt, L.I.C.S.W., Ph.D., State Opioid Treatment Authority	
	Kimberley Heine, Forensic Toxicologist, QA/QC Program Manager	
	Tayiana Reed PharmD, MS, AAHIVP, ACE, RPh, Pharmacist	
	Careen-Joan Franklin PharmD, RPh, Pharmacist	
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	
	Laurel Alcenat, MBA, Program Specialist	
	Monai Lowe, PharmD, RPh, PDMP Pharmacist	
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	
VISITORS:		

Open Session Agenda
Quorum:

0820-O-01	<p><u>Welcome & Introductions</u></p> <p><u>Chair Report</u></p> <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <p>(a) On the implementation and evaluation of the Program;</p> <p>(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</p> <p>(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</p> <p>(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</p> <p>(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</p> <p>(f) Regarding the design and implementation of educational courses for:</p> <p>(1) Persons who are authorized to access the prescription monitoring information;</p> <p>(2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;</p> <p>(3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and</p> <p>(4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.</p>	Aisha Nixon
0820-O-02	<p><u>Approval of January 2024 PDMP Advisory Committee Meeting Minutes</u></p> <p>(a) Minutes from the January 2024 Meeting</p>	
0820-O-03	<p><u>Welcome of the new committee members</u></p>	

0820-O-04	<p><u>Report from Attorney Advisor</u> No Report</p>																																																																																					
0820-O-05	<p><u>Program Updates</u></p> <p>(a) PDMP Registration Statistics and Compliance</p> <table border="1" data-bbox="492 380 1349 1171"> <thead> <tr> <th>Licensed Professional</th> <th>Number of DC Licensed Active Professionals</th> <th>Number of Registered PDMP Users</th> <th>Percentage of DC Licensed Active Professionals Registered with the PDMP</th> </tr> </thead> <tbody> <tr><td>Physician</td><td>15,839</td><td>13965</td><td>88%</td></tr> <tr><td>Physician Assistant</td><td>1,335</td><td>1,164</td><td>87%</td></tr> <tr><td>Advanced Practice Nurse</td><td>3,849</td><td>3,536</td><td>92%</td></tr> <tr><td>Pharmacist</td><td>2,236</td><td>2,085</td><td>93.0%</td></tr> <tr><td>Dentist</td><td>1,175</td><td>1,097</td><td>93%</td></tr> <tr><td>Veterinarian</td><td>472</td><td>418</td><td>89%</td></tr> <tr><td>Podiatrist</td><td>130</td><td>128</td><td>98%</td></tr> <tr><td>Optometrist</td><td>197</td><td>189</td><td>96%</td></tr> <tr><td>Naturopathic Physician</td><td>63</td><td>53</td><td>84%</td></tr> <tr><td>VA Prescriber</td><td></td><td>285</td><td></td></tr> <tr><td>VA Dispenser</td><td></td><td>42</td><td></td></tr> <tr><td>Pharmacy Technician or Delegate</td><td>1,232</td><td>4</td><td>-</td></tr> <tr><td>Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)</td><td></td><td>33</td><td></td></tr> <tr><td>Total</td><td>25,296</td><td>22,635</td><td>89%</td></tr> </tbody> </table> <p>*Current as of 08/2/2024</p> <p>(b) Outreach Activity</p> <p>Outreach activities since the January 2024 meeting:</p> <table border="1" data-bbox="492 1335 1438 1696"> <thead> <tr> <th>Date of Event</th> <th>Name of Event</th> <th>Type of Event</th> <th>Topics Discussed</th> <th>Audience</th> <th>Number of Participants</th> </tr> </thead> <tbody> <tr> <td>2/27/24</td> <td>Treatment for Opioid Use Disorder in Carceral Settings</td> <td>CE webinar</td> <td>Opioids</td> <td>DC prescribers and dispensers</td> <td>153</td> </tr> <tr> <td>6/17/24</td> <td>The Pharmacist's Role in Managing Patients with Opioid Use Disorder</td> <td>CE Webinar</td> <td>Opioids</td> <td>DC prescribers and dispensers</td> <td>90</td> </tr> <tr> <td>8/15/24</td> <td>The New Language of Drugs</td> <td>CE Webinar</td> <td>Illicit Opioids</td> <td>DC prescribers and dispensers</td> <td>116</td> </tr> </tbody> </table>	Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP	Physician	15,839	13965	88%	Physician Assistant	1,335	1,164	87%	Advanced Practice Nurse	3,849	3,536	92%	Pharmacist	2,236	2,085	93.0%	Dentist	1,175	1,097	93%	Veterinarian	472	418	89%	Podiatrist	130	128	98%	Optometrist	197	189	96%	Naturopathic Physician	63	53	84%	VA Prescriber		285		VA Dispenser		42		Pharmacy Technician or Delegate	1,232	4	-	Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33		Total	25,296	22,635	89%	Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants	2/27/24	Treatment for Opioid Use Disorder in Carceral Settings	CE webinar	Opioids	DC prescribers and dispensers	153	6/17/24	The Pharmacist's Role in Managing Patients with Opioid Use Disorder	CE Webinar	Opioids	DC prescribers and dispensers	90	8/15/24	The New Language of Drugs	CE Webinar	Illicit Opioids	DC prescribers and dispensers	116	Dr. Ortique
Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP																																																																																			
Physician	15,839	13965	88%																																																																																			
Physician Assistant	1,335	1,164	87%																																																																																			
Advanced Practice Nurse	3,849	3,536	92%																																																																																			
Pharmacist	2,236	2,085	93.0%																																																																																			
Dentist	1,175	1,097	93%																																																																																			
Veterinarian	472	418	89%																																																																																			
Podiatrist	130	128	98%																																																																																			
Optometrist	197	189	96%																																																																																			
Naturopathic Physician	63	53	84%																																																																																			
VA Prescriber		285																																																																																				
VA Dispenser		42																																																																																				
Pharmacy Technician or Delegate	1,232	4	-																																																																																			
Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33																																																																																				
Total	25,296	22,635	89%																																																																																			
Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants																																																																																	
2/27/24	Treatment for Opioid Use Disorder in Carceral Settings	CE webinar	Opioids	DC prescribers and dispensers	153																																																																																	
6/17/24	The Pharmacist's Role in Managing Patients with Opioid Use Disorder	CE Webinar	Opioids	DC prescribers and dispensers	90																																																																																	
8/15/24	The New Language of Drugs	CE Webinar	Illicit Opioids	DC prescribers and dispensers	116																																																																																	
0820-O-06	<p><u>Grant Updates</u></p> <p>(a) Districtwide Gateway Integration</p> <p>A total of 125 health entities have connected to the DC PDMP through Gateway Integration in total since integration began in 2019.</p>	Dr. Ortique																																																																																				

	<p>(b) DC Gateway Integration Communication Campaign Spanned 4/29/24-7/1/24</p> <p>Consisted of 6 emails that were sent to registered AWAxE users who have accessed the DC PDMP in the last year via the web portal only</p> <p>The campaign resulted in 17 new integration requests in DC since the campaign launch</p> <p>(c) 2024 PDMP Administrators National Forum Occurred May7-9, 2024 in San Antonio, Texas DC PDMP staff had the opportunity to network with other PDMP Administrators and present on our program and grant related projects</p>	
0820-O-07	<p><u>Presentation</u> DC Prescription Drug Monitoring Program Updates(attached)</p> <p>Bamboo Health Solutions Overview: Overdose Insights and Opioid Treatment Program Reporting Presented by: Jacob Cooper, Vice President of State Accounts, Bamboo Health</p>	Dr. Ortique Mr. Cooper
0820-O-08	<p><u>Action Items</u></p> <ul style="list-style-type: none"> • PDMP Advisory Committee potential recommendation(s) • Potential Future meeting date 	Dr. Ortique
0820-O-09	Other news/highlights from Committee members	
Comments from the Public		
Motion to Adjourn the Open Session	<p>Madam Chair, I move that the Committee close the meeting.</p> <p>(Roll Call Vote)</p>	

This concludes the meeting.

Meeting Adjourned __:__

**Government of the District of Columbia
Department of Health**

**Prescription Drug Monitoring Program
Advisory Committee Meeting**

**899 NORTH CAPITOL ST. NE – 2ND FLR.
WASHINGTON, DC 20002**

WebEx In-person MEETING

**January 16, 2024
10:08 AM—11:38 AM**

AGENDA

CALL TO ORDER: 10:08 am

PRESIDING: Aisha Nixon

COMMITTEE MEMBERSHIP/ATTENDANCE:

ADVISORY COMMITTEE MEMBERS:		
	Jacqueline Watson, DO, MBA, DC Health Chief of Staff	Absent but represented by Aisha Nixon
	Justin Ortique, PharmD, RPh, CPM, Board of Pharmacy Executive Director, Program Manager Pharmaceutical Control Division	Present
	Sithembile Chithenga, MD, MPH Board of Medicine Executive Director	Present
	Vito R. DeIvento, DVM, MS, Board of Veterinary Medicine Executive Director, Program Manager Animal Services Program	Absent
	Teresa Walsh, PhD, RN, NE-C, Board of Nursing Executive Director	Present
	Natalie Kirilichin, MD, MPH, Emergency Medicine Physician	Present
	Sheri Doyle, MPH, Consumer Member	Absent
	Captain Shawn Rooney, Metropolitan Police Department	Present
	Careen-Joan Franklin, PharmD, RPh, Pharmacist	Present
	Sharon Hunt, L.I.C.S.W., Ph.D., State Opioid Treatment Authority	Present
	Kimberley Heine, Forensic Toxicologist, QA/QC Program Manager	Present
	Tayiana J Reed, Pharm D, MS, AAHIVP, RPH, Pharmacist	Present
PDMP STAFF:	Reginal Bellamy, PharmD, RPh, Supervisory Pharmacist	Present
	Uche Ekwomadu, MPH, MPharm, Public Health Analyst	Present
	Laurel Alcenat, MBA, Program Specialist	Present
LEGAL STAFF:	Carla Williams, Esq, Senior Assistant General Counsel, PDMP Attorney Advisor	Present
VISITORS:	Kera Johnson, Policy Analyst, Office of Government Relations	
	Joe Carhart, Data Scientist, Bamboo Health	

Open Session Agenda

Quorum:

0116-O-01	<p><u>Welcome New Committee Members & Introductions</u></p> <ul style="list-style-type: none"> • Sharon Hunt, L.I.C.S.W., Ph.D. (Department of Behavioral Health) • Kimberley Heine, MFS (Office of the Chief Medical Examiner) • Tayiana J Reed PharmD, MS, AHIVP, RPH (Department of Healthcare Finance) <p><u>Chair Report</u></p> <ul style="list-style-type: none"> • DC Health Moves its Headquarters to 2201 Shannon Place SE – effective February 26, 2024 • Opioid Abatement Advisory Commission <p><u>Charge of the Committee</u></p> <p>The Committee shall convene at least two (2) times per year to advise the Director:</p> <p>(a) On the implementation and evaluation of the Program;</p> <p>(b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;</p> <p>(c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;</p> <p>(d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;</p> <p>(e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and</p> <p>(f) Regarding the design and implementation of educational courses for:</p> <ol style="list-style-type: none"> (1) Persons who are authorized to access the prescription monitoring information; (2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program; (3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and (4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program. 	Dr. Watson (represented by Aisha Nixon)
-----------	---	--

0116-O-02	<p><u>Approval of August 2023 PDMP Advisory Committee Meeting Minutes</u></p> <p>(a) Minutes from the August 2023 Meeting</p> <p>Motion: Board member Dr. Justin Ortique made the motion to approve the August 2023 meeting minutes.</p> <p>Seconded by: Board Member, Dr. Careen-Joan Franklin</p> <p>Roll Call Vote:</p> <ul style="list-style-type: none"> ○ Dr. Justin Ortique ○ Dr. Careen-Joan Franklin ○ Dr. Teresa Walsh ○ Dr. Sithembile Chithenga ○ Dr. Natalie Kirilichin ○ Captain Shawn Rooney ○ Dr. Sharon Hunt ○ Dr. Tayiana J Reed ○ Kimberley Heine <p>Absentations: Dr. Vito R. DeVento</p> <p>Motion Carried</p>	
0116-O-03	<p><u>Overview of DC PDMP Program</u></p> <p>DC Prescription Drug Monitoring Program Overview and Updates(attached) Justin Ortique, PharmD, RPh, CPM Executive Director/Program Manager, HRLA</p> <ul style="list-style-type: none"> • Dr. Ortique gave a presentation on the PDMP and any new updates since the last meeting • Guest Presentation by Joe Carhart on the Overdose Risk Score for the NarxCare patient report • Dr. Ortique mentioned having 1-2 provider education courses related to the PDMP • Possible idea to collaborate with DHCF to provide some education on prior authorizations and tools available to assist providers • Dr. Reed mentioned that DHCF has quarterly provider meetings with healthcare finance. They'll be happy to put this item on their agenda as a topic to reach the pharmacy providers in the district 	Dr. Ortique
0116-O-04	<p><u>Report from Attorney Advisor</u></p> <p>PDMP Legislative Update Update on PDMP Amendment Act of 2023</p> <ul style="list-style-type: none"> • Expands the authority of the Director of the Department of Health to disclose information related to the prescribing and dispensing of covered substances, and to authorize the Director to charge a fee to offset the operational costs of expanding disclosure to information. <p><i>Carla Williams briefly explained that the DOH accepted a recommendation from this committee to move forward with proposing legislation to expand the authority of the Director of the Department of Health to disclose information related to the prescribing and dispensing of covered substances and to authorize the director to charge a fee to offset the operational cost of expanding disclosure of information.</i></p>	Ms. Williams

This legislation has made it through the counsel and the mayor. The Next step is the congressional review period. As of yet, there's no projected date.

The act was returned by the mayor on 12/22/23 and it was published in the registrar on 12/29/23.

Once the congressional review period is completed, the bill becomes an official law and we can then proceed with implementing those new changes to the program.

0116-O-05

PDMP Registration Statistics and Compliance Report

Dr. Ortique

Licensed Professional	Number of DC Licensed Active Professionals	Number of Registered PDMP Users	Percentage of DC Licensed Active Professionals Registered with the PDMP
Physician	12,966	12,366	95.37%
Physician Assistant	1,201	1,091	90.84%
Advanced Practice Nurse	4,224	3,730	88.30%
Pharmacist	2,126	2,038	95.86%
Dentist	1,241	1,134	91.38%
Veterinarian	521	475	91.17%
Podiatrist	155	147	94.84%
Optometrist	230	215	93.48%
Naturopathic Physician	63	53	84.13%
VA Prescriber		285	
VA Dispenser		42	
Pharmacy Technician or Delegate	1,081	4	
Other (Licensing Board Investigator, Law Enforcement, Medical Examiner, Admin)		33	
Total	22,727	21,249	93.5%

***Current as of 12/11/2023**

- Since the August 2023 meeting there has been a 2,474 (4%) registration increase in overall compliance

Committee member Dr. Justin Ortique explained how the registration process worked for new practitioners and that there has been a 4% registration increase since August 2023. The ultimate goal is to be at 100%.

Dr. Walsh mentioned that during this upcoming renewal period for the APRNs there will be a focus to get them to comply with the PDMP registration requirement. There's talks with IT to have a hard stop for them during registration to make sure they are registered for the PDMP.

0116-O-06	<p><u>Engagement and Outreach Activities</u></p> <p>Outreach activities since the August 2023 meeting:</p> <table border="1" data-bbox="446 346 1318 693"> <thead> <tr> <th>Date of Event</th> <th>Name of Event</th> <th>Type of Event</th> <th>Topics Discussed</th> <th>Audience</th> <th>Number of Participants</th> </tr> </thead> <tbody> <tr> <td>9/20/23</td> <td>Board of Dentistry Meeting</td> <td>Presentation</td> <td>DC PDMP</td> <td>BOD and Public</td> <td>25</td> </tr> <tr> <td>11/1/23</td> <td>Board of Nursing Meeting</td> <td>Outreach</td> <td>DC PDMP</td> <td>BON Board members and staff</td> <td>~20</td> </tr> <tr> <td>11/15/23</td> <td>DCRx Learner Experience Survey 2022</td> <td>Survey</td> <td>Educational Topics of Interest</td> <td>DC prescribers and dispensers</td> <td>~18,00</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Plan on having more outreach activities. Will communicate with committee members on ways we can do outreach 	Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants	9/20/23	Board of Dentistry Meeting	Presentation	DC PDMP	BOD and Public	25	11/1/23	Board of Nursing Meeting	Outreach	DC PDMP	BON Board members and staff	~20	11/15/23	DCRx Learner Experience Survey 2022	Survey	Educational Topics of Interest	DC prescribers and dispensers	~18,00	Dr. Ortique
Date of Event	Name of Event	Type of Event	Topics Discussed	Audience	Number of Participants																					
9/20/23	Board of Dentistry Meeting	Presentation	DC PDMP	BOD and Public	25																					
11/1/23	Board of Nursing Meeting	Outreach	DC PDMP	BON Board members and staff	~20																					
11/15/23	DCRx Learner Experience Survey 2022	Survey	Educational Topics of Interest	DC prescribers and dispensers	~18,00																					
0116-O-07	<p><u>Presentation from DBH</u></p> <p>DBH Updates Concerning the Opioid Epidemic Sharon Hunt, L.I.C.S.W., Ph.D., DBH</p> <p><i>Dr. Sharon Hunt presented on opioids and things going on at the Department of Behavioral Health</i></p> <p><i>LLDC is the underlying strategic framework that guides opioid fund investments. Their prevention priorities include:</i></p> <ul style="list-style-type: none"> <i>Expand naloxone distribution to business and other community entities and the pharmacy program; make naloxone readily available</i> <i>Enhance prevention initiatives and the workforce</i> 	Dr. Hunt																								
0116-O-08	<p><u>Next meeting Dates</u></p> <ul style="list-style-type: none"> August 13, 2024 (virtual) December 10, 2024 (in-person) 	Dr. Ortique/ Dr. Watson																								
0116-O-09	<p>Other news/highlights from Committee members</p> <p>Dr. Ortique requested committee members to present on different relevant topics at future committee meetings. The presentation should be about how their area can contribute regarding the PDMP. Captain Rooney mentioned that he doesn't mind presenting during the next meeting. Attorney Williams mentioned to Captain Rooney that we've previously asked for some suggestion or recommendations to the committee on how we can help coming up with something that will help reduce the overdoses that are being seen from a law enforcement point of view.</p>																									
Comments from the Public	<i>No comments from the public</i>																									
Motion to Adjourn the Open Session	<p>Madam Chair, I move that the Committee close the meeting.</p> <p>Motion: <i>Dr. Ortique made the motion that the Committee close the meeting.</i></p> <p>Seconded by: <i>Committee Member, Dr. Teresa Walsh</i></p>	Dr. Watson (represented by Aisha Nixon)																								

<p>Roll Call Vote:</p> <ul style="list-style-type: none">○ Dr. Justin Ortique○ Dr. Teresa Walsh○ Dr. Sithembile Chithenga○ Dr. Natalie Kirilichin○ Captain Shawn Rooney○ Dr. Sharon Hunt○ Dr. Tayiana J Reed○ Kimberley Heine○ Dr. Careen-Joan Franklin <p>Abstentions: None.</p> <p>Motion Carried.</p>	
--	--

This concludes the meeting.
Meeting Adjourned 11:38 am

This meeting is governed by the Open Meetings Act. Please address any questions or complaints arising under this meeting to the Office of Open Government at opengovoffice@dc.gov.

DC Prescription Drug Monitoring Program Program Updates

August 2024 PDMP Advisory Committee Meeting

Justin Ortique PharmD, RPh, CPM


VISION

To be the healthiest city in America

MISSION

The District of Columbia Department of Health promotes health, wellness and equity across the District, and protects the safety of residents, visitors and those doing business in our nation's capital.

DC HEALTH ORGANIZATION STRUCTURE




07/23/2024

———— Direct Report - - - - Indirect Report

21st Century Public Health Leadership: Transforming DC Health

Role of DC Health



DC Health Strategic Priorities

- Promote a Culture of Health and Wellness
- Address the Social Determinants of Health
- Strengthen Public-Private Partnerships
- Close the Chasm between Clinical Medicine and Public Health
- Implement a data-driven outcome-oriented approach to program and policy development

Charge of the Committee

- The Committee shall convene at least two (2) times per year to advise the Director:
 - (a) On the implementation and evaluation of the Program;
 - (b) On the establishment of criteria for indicators of possible misuse or abuse of covered substances;
 - (c) On standardization of the methodology that should be used for analysis and interpretation of prescription monitoring data;
 - ★ (d) In determining the most efficient and effective manner in which to disclose the findings to proactively inform prescribers regarding the indications of possible abuse or misuse of covered substances;
 - (e) On identifying drugs of concern that demonstrate a potential for abuse and that should be monitored; and
 - (f) Regarding the design and implementation of educational courses for:
 - (1) Persons who are authorized to access the prescription monitoring information;
 - (2) Persons who are authorized to access the prescription monitoring information, but who have violated the laws or breached professional standards involving the prescribing, dispensing, or use of any controlled substances or drugs monitored by the Program;
 - (3) Prescribers on prescribing practices, pharmacology, and identifying, treating, and referring patients addicted to or abusing controlled substances or drugs monitored by the Program; and
 - (4) The public about the use, diversion and abuse of, addiction to, and treatment for the addiction to controlled substances or drugs monitored by the Program.

Grant Updates

Grant Awards

- The DC PDMP has received funding from two grants to support the existing infostructure
- The grant awards come from the Bureau of Justice Assistance (BJA) for the Harold Rogers PDMP grant and the CDC for the Overdose Data to Action in States grant
- BJA has since released a grant enhancement that will provide up to 1 million dollars in additional enhancement funding the next two years


Grant Awards cont.

- The grant enhancement will be used to fund additional projects and continue to support staff

Potential Projects

Advanced Analytics Enhancement

- Funding will be used to support the advanced analytics package of the DC PDMP
- The advanced analytics package is used to pull information for data requests as well as the annual report
- The enhancement will support customization to allow to breakdown data at the Ward level



Opioid Treatment Program (OTP)

- Funding will potentially be used to support the addition of OTP data into the DC PDMP
- Initially recommended by the DC Opioid Fatality Review Board
- 42 CFR Part 2 - allows for this data to be submitted to the PDMP with patient consent

Opioid Treatment Program (OTP)

- The OTP data integration will provide the DC PDMP with the ability to display an indicator and a tile with opioid treatment program data on a patient report
- The purpose is to improve patient care by providing clinicians with additional insight into patients with substance use disorder.
- The information will be secure and not eligible to be reviewed by law enforcement

Non-fatal and Fatal Overdose Reporting

- The DC PDMP is exploring provider notifications to of non-fatal overdoses and fatal overdoses
- The purpose is to improve patient safety, enhance clinical decision making and ultimately reduce the incidence of drug overdoses within the District of Columbia
- Other data sources will be utilized and would appear with in the DC PDMP
- Other states have used this overdose information successfully to prevent disruption of patient services and to provide targeted interventions.